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Abstract
The dyslipidemia pattern usually associated with childhood obesity consists of a
combination of elevated triglyceridemia, decreased plasma high density lipoprotein
cholesterol concentration and LDL-c concentration at the upper limit of the normal
range. This type of dyslipidemia is associated with dense and small LDL, which are
proatherogenic. High circulating levels of oxidized LDL were described in extreme
pediatric obesity, in children with high fructose intake and are associated with insulin
resistance. The worst effect on blood lipids have trans and saturated fatty acids. But
the amount of total energy intake plays more important role in lipid profiles. In
childhood obesity it seems that insulin resistance precedes the development of the
metabolic syndrome feature and insulin resistance is correlated with dyslipidemia.
Insulin resistance increases free fatty acid flux to the liver by decreased inhibition of
lipolysis and also by increased de novo lipogenesis. Fish oil is rich in eicosapentaenoic
acid (EPA) and docosahexaenoic acid (DHA) and has hypotriglyceridemic effect in
comparison to monounsaturated fatty acids. Passive in utero exposure to a hyperli‐
pidemic environment may have programmed these children for accelerated athero‐
sclerosis. The infant formula should be enriched with long chain fatty acids because
this supplementation is associated with lower blood pressure during later childhood.
In obese children, supplements with Omega-3 polyunsaturated fatty acids improve
lipid profile, blood pressure values and inflammatory markers. Omega-3 fatty acids
prevent metabolic syndrome, by reducing hepatic steatosis, visceral fat, by reducing
serum triglycerides and improving insulin sensitivity. Potentially all compounds of
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the Sea buckthorn berry, including flavonols, carotenoids, fatty acids, tocopherols and
phytosterols can affect the metabolic profile. Special features of the berry oils are high
proportions of palmitoleic acid as well as vitamin E, carotenoids, and sterols. The
palmitoleic acid stimulates muscle insulin action, suppresses hepatosteatosis and
prevent the deleterious effects of saturated fatty acids and high glucose on human
pancreatic beta-cell turnover and function. Phenolic compounds and flavonoids from
sea buckthorn ameliorate bodyweight, blood glucose, and serum lipid profile. By
reducing triglyceridemia and by improving the blood pressure levels, sea buckthorn
pulp oil may prevent metabolic syndrome in obese children. The treatment is
recommended in hypertriglyceridemic waist phenotype obese children. Omega-3
supplements and sea buckthorn pulp oil supplements reversed the carotid intima
media thickness values in obese children and they have beneficial effects in childhood
obesity
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1. Introduction
The World Health Organization (WHO) regards childhood obesity as one of the most serious
global public health challenges for the 21st century. Childhood obesity is associated with a
higher chance of obesity, premature death, and disability in adulthood. But in addition to
increased future risks, overweight and obese children are at an increased risk of developing
various health problems. Visceral obesity leads to insulin resistance, mediated by free fatty
acids and adipokines [1, 2].
The present review deals with the management of obesity and dyslipoproteinemia in child‐
hood and emphasis the beneficial effects of supplements with Omega-3 fatty acids and Sea-
buckthorn (Hippophae rhamnoides) pulp oil obtained by cold pressing.
2. Dyslipidemia in childhood obesity
The dyslipidemia pattern usually associated with childhood obesity consists of a combina‐
tion of elevated triglyceridemia, decreased plasma level high-density lipoprotein cholester‐
ol (HDL-c) concentration, and low-density lipoprotein cholesterol (LDL-c) concentration at
the upper limit of the normal range. According to the nuclear magnetic resonance spectro‐
scopy results, this type of dyslipidemia is associated with dense and small LDL, less stable
HDL, a reduction in total  HDL-c,  and in large HDL particles [3].  Small  and dense LDL
particles  are  associated  also  with  visceral  fat  and  insulin  resistance.  In  school-age  chil‐
dren, greater total and central adiposity are associated with smaller LDL particle size and
lower HDL-c plasma levels [4].
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The LDL can be easily oxidized; they have low affinity for LDL receptors and they penetrate
the intima [5]. The macrophages from the vessel wall take the oxidized LDL and they are
transformed into foam cells, and so the process of atherosclerosis starts. GGT (Gamma
Glutamyl Transpeptidase), an enzyme known to modulate the redox status of the thiol
proteins, can also catalyze the oxidation of LDL from the circulation, augmenting the devel‐
opment of atherosclerosis [6]. In the plasma, GGT constitutes complexes with albumin and
lipoproteins [7]; while in the atheromatous plaques, GGT is colocalized with oxidized LDL
and foam cells [8].
HDL inhibits LDL oxidation. The antioxidant activity of HDL can be explained by its proteins,
which link transitional metals, and by two intrinsic enzymatic systems: acetylhydrolase and
paraoxonase [9].
High circulating levels of oxidized LDL were described in extreme pediatric obesity [10] in
children with high fructose intake [11] and are associated with insulin resistance [12].
More than half of the obese children have dyslipidemia. Improper dietary habits, such as fast
foods and snacks, rich in saturated and trans-fatty acids have an important contribution for
dyslipidemia. Decreased physical activity and unhealthy eating habits are noticed to have
higher incidence in adolescents. These lifestyle modifications, increased susceptibility to
insulin resistance, and hormonal changes make pubertal subjects prone to metabolic syn‐
drome. Dyslipidemia present in metabolic syndrome (hypertriglyceridemia and low HDL-c)
is associated with insulin resistance, with inflammatory markers (C reactive protein) and with
a protrombotic status [13, 14, 15].
In a recent study [16] done on 139 children, the prevalence of dyslipidemia among overweight
and obese children was 50.4%. Dyslipidemia patterns were: hypertriglyceridemia 31.9%, low
HDL-c 29.7%, high non-HDL-c 15.8%, hypercholesterolemia 11.9%, and elevated LDL-c 10.7%.
The dyslipidemia was often (> 50%) present among those with increased waist circumference
and family history of dyslipidemia.
The consumption of fructose has recently increased and it seems that in adolescents, fructose
represents 12% of the total daily intake [11]. In overweight children, higher fructose intake
from sweets and sweetened drinks predicts smaller LDL particle size [4].
Although the caloric intake from fat and different types of fatty acids influence the plasma
lipid profile, the amount of total energy intake plays a more important role in lipid profiles [17].
The worst effect on blood lipids have trans and saturated fatty acids [18]. Partially hydrogen‐
ated vegetable oil or fish oil are very rich in trans fatty acids that increase LDL-c and decrease
HDL-c, so they must be avoided in the diet. C12-16 saturated fatty acids increase both LDL-c
and HDL-c levels, but stearic acid has a neutral effect on the plasma lipid profile comparable
to that of oleic acid [19].
Replacement of saturated fatty acids by polyunsaturated fatty acids (PUFA) or monounsatu‐
rated fatty acids (MUFA) lowers both LDL-c and HDL-c [20].
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Supplementation with MUFA is supported by authoritative bodies. When MUFA replaces
saturated fatty acids it reduces total cholesterol, and when MUFA replaces carbohydrates it
decreases triglycerides and increases HDL [21].
The atherogenic lipid profile is more severe in obese children, especially in boys, who are
insulinoresistent. The severity of obesity estimated by the value of body mass index (BMI)
is  of  a  lesser  importance in  comparison with insulin resistance on the atherogenic  lipid
profile [22].
The atherogenic index can be calculated in many ways, but the most used procedures are: as
the ratio between total cholesterol to HDL cholesterol or as a ratio apoB/apoA1. By assessing
atherogenic indexes, it has been demonstrated that overweight and obese children have twice
higher risk of atherosclerosis [23] and that advancing puberty and advancing age are athero‐
genic risk factors for obese boys [24].
The relation between plasma lipids and prediabetes in obese prepubertal children is proved
by the association of saturated fatty acids in triglycerides with the HOMA-IR (homeostatic
model assessment of insulin resistance) [25].
In children, the process of atherosclerosis starts at an early age and is linked to visceral obesity
[26]. The common carotid artery intima-media thickness (C-IMT) measured by ultrasound
imaging is a marker of preclinical atherosclerosis. C-IMT relates to the severity and extent of
coronary artery disease and predicts the likelihood of cardiovascular events in adults.
True primary prevention of atherosclerosis, as contrasted with primary prevention of clinically
manifest atherosclerotic disease, must begin in childhood or adolescence [27].
Results from the Young Finns Study have shown that conventional childhood risk factors, such
as dyslipidemia, obesity, elevated blood pressure, and smoking, are predictive of subclinical
atherosclerosis in young adults [28]. The same authors of the study underline the good news
that the adverse cardiometabolic effects of childhood overweight/obesity are reversed among
those who become nonobese adults.
The relation cause-effect between dyslipidemia and insulin resistance is not well established
but they are interdependent. Most of the researchers consider that insulin resistance precedes
the development of the metabolic syndrome feature, including dyslipidemia [29].
Insulin resistance increases free fatty acid flux to the liver by decreased inhibition of lipolysis
and also by increased de novo lipogenesis [30].
Supplements with docosahexaenoic acid (DHA) reduce plasma concentrations of free fatty
acids of LDL-c and the ratio triacylglycerols/HDL-c, improving insulin resistance [31].
Eicosapentaenoic acid (EPA) increases the anti-inflammatory monocyte cytokine IL-10
expression and reduces arterial stiffness, which may contribute to the antiatherogenic effect
of EPA in obese dyslipidemic patients [32].
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2.1. Effects of MUFA and PUFA supplements on dyslipidemia associated to childhood
obesity
The MUFA from n-7 and n-9 classes can be synthesized in our body from acetyl-coA, but the
essential PUFA from n-3 and n-6 classes are required in the diet. A balance between n-6 and
n-3 PUFA must be maintained in the diet. There is no consensus about the value of this ratio,
but the most used value is around 5. Linoleic acid (C18 delta 9,12) represents the parental fatty
acid for class n-6 and linolenic acids (C18 delta 9,12,15) for class n-3, respectively. Naturally,
the structure of unsaturated fatty acids is cis fatty acids. PUFA are incorporated in the structure
of membrane phosphatides involved in cell fluidity, permeability, and signal transduction. n-3
PUFA are important in the brain development in the fetus and also in early postnatal life [19].
Differences in the composition of dietary fat may also contribute to adipose tissue development
by altering rates of adipocyte differentiation and proliferation. Relatively low intake of n-3
PUFA and excessive dietary linoleate may contribute to excessive adipose tissue [33].
Postmortem examination of fetuses delivered from hypercholesterolemic mothers demon‐
strated that passivity in utero exposure to a hyperlipidemic environment may have program‐
med these children for accelerated atherosclerosis [34].
It was demonstrated that an enhanced maternal-fetal n-3 PUFA status was associated with
lower childhood adiposity [35]. But, in another study, supplementation with n-3 fatty acids
during pregnancy and lactation didn’t influence significantly the fat mass in the offspring
during the first year of life [36]. Good news is that fish oil supplementation during lactation
affects blood pressure and body composition of children [37] and that nutritional interventions
may improve plasma long-chain PUFA profile and metabolic outcomes of normolipidaemic
obese children [38].
According to the European directive, the infant formula should be enriched with long-chain
PUFA because this supplementation is associated with lower blood pressure during later
childhood. In clinical studies done in adults, fish oil supplementation gave varying results on
blood pressure values but most of them showed a lowering in the blood values [19].
A decrease in serum n-3 PUFA, especially DHA, and an increase in saturated FA was noticed
in obese children versus lean controls. The subcutaneous adipose tissue and not the visceral
adipose tissue was correlated to the changes in PUFA and saturated FA, suggesting an
abnormal essential FA metabolism in obese adolescents [39].
Fish oil is rich in EPA and DHA and has a hypotriglyceridemic effect in comparison to MUFA,
but supplementation only with DHA does not share the hypotriglyceridemic effect. Fish may
be more beneficial than fish oil supplementation. The favorable effect of cis-MUFA on
cardiovascular diseases is unlikely, but of those n-3 PUFA is suggestive [19].
Omega-3 PUFA supplementation was associated with a reduced level for triglycerides and an
up-regulated expression of the gene encoding peroxisome proliferator activated receptor-α
(PPARα), a transcription factor that increases fatty acid oxidation and down-regulates pro-
inflammatory genes [40].
Obese Childhood Dyslipidemia Management Beyond Statins — MUFA, PUFA, and Sea-buckthorn Supplements
http://dx.doi.org/10.5772/61001
63
Omega-3 fatty acids can prevent prediabetes and diabetes mellitus development because these
PUFA are ligands for peroxisome proliferator receptor activator gamma (PPARγ) involved in
insulin sensitivity and also, by constituting of the novel biologically active lipid mediators
(resolvins and protectins), which also increase insulin sensitivity. The obesity-induced hepatic
steatosis can be prevented by Omega-3 PUFA because they decrease endogenous lipid
production by inhibiting the expression of the transcription factor, sterol response element
binding protein-1c, SREBP-1c [41].
In accordance with the above molecular effects, beneficial effects of Omega-3 PUFA in obesity
were demonstrated in clinical and experimental studies. It was shown that Omega-3 fatty acids
prevent metabolic syndrome by reducing hepatic steatosis and visceral fat, by reducing serum
triglycerides, and improving insulin sensitivity [42, 43].
Omega-3 fatty acids, by inhibiting hepatic lipogenesis, reduce a jéun and postprandial
triglyceridemia [44] and improve the quality of platelets membrane phospholipids. In
extrahepatic tissues, the activation of lipoprotein lipase has also a great contribution to the
hypotriglyceridemic effect of Omega-3 fatty acids. They have also an antiatherogenic effect by
reducing the quantity of small and dense LDL [45].
Many clinical and experimental studies have demonstrated that omega-3 PUFA have lipid-
lowering effects. The improvement in lipid profile is due mainly to enhanced fatty acid beta-
oxidation and suppression of fatty acid synthesis in the liver [46, 47, 48, 49].
During PUFA treatment,  the gene expression of  the lipogenesis  enzyme sterol  regulator
element binding protein-1c (SREBP-1c) is decreased while the fatty acid oxidation in the
liver is increased via the activation of peroxisome proliferator activated receptor-α (PPAR-
α) [50, 51].
Dyslipidemia and insulin resistance are associated with non-alcoholic fatty liver disease
(NAFLD). Diet rich in lipids and augmented lipolysis in adipose tissues increase the hepatic
pool of fatty acids for the liver. Hyperglycaemia and hyperinsulinemia increase lipogenesis in
the liver and contribute to hepatic steatosis [52, 53].
Omega-3 PUFA have beneficial effects in liver steatosis by decreasing triglyceridemia and by
reducing the muscle intramyofibrillar triglycerides [51].
By upregulating the genes involved in insulin sensitivity, namely glucose transporters
(GLUT-2/GLUT-4), peroxisome proliferator activated receptor-γ (PPAR-γ), and insulin
receptor signaling (IRS-1/IRS-2) [41], Omega-3 PUFA increase insulin sensitivity.
Lipid intake should represent 25–35% of total energy intake. In USA, saturated FA represents
11% of total energy intake, PUFA 7%, and MUFA 12%. Excess consumption of fatty acids,
above the intake recommended, lead to weight gain that is detrimental for body health [21].
When in the diet, saturated fatty acids and trans fatty acids are replaced by cis-MUFA and
PUFA, plasma levels for total cholesterol and LDL-c are reduced, while HDL-c concentration
remains unchanged. According to the value of the calculated atherogenic index (total choles‐
terol/HDL-c), this should mean a beneficial effect. Diets rich in cis-MUFA and PUFA may
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improve insulin sensitivity; and cis-MUFA compared with carbohydrate and saturated fatty
acids reduced HOMA-IR values [19].
When replacing carbohydrate and saturated fat, MUFA consumption can be beneficial. MUFA
has positive impact on surrogate markers, but the potential impact on disease outcome remains
unclear. When MUFA replaces saturated fatty acids it reduces total cholesterol and when
MUFA replaces carbohydrates it decreases triglycerides and increases HDL [21].
Nowadays, the recommendation is to replace solid fats with oils rich in MUFA and PUFA and
the most recommended diet is the Mediterranean diet. A randomized controlled trial done on
7,000 patients demonstrated that Mediterranean diet beats low-fat diet. In the study, the two
groups of subjects with Mediterranean diet that were supplemented with either olive oil
(approximately 4 tablespoons/day) or nuts (average of 3 servings/day) versus the group with
low-fat diet reduced the risk for major cardiovascular events [54].
2.2. Effects of supplements with Sea-buckthorn fractions on dyslipidemia associated to
childhood obesity
Sea-buckthorn (Hippophae rhamnoides) is a plant of seashores and cliffs; it can be found in
Central Asia and Europe, all the way from the shores of the Black Sea to the northwestern
shores of the continent. In addition, Sea-buckthorn has spread to Canada and the United States
and nowadays the plant has been currently domesticated. Both the berries and the leaves of
the plant can be used as dietary supplements.
According to Greek legend, the sick and wounded horses of warriors would be allowed to
roam and feed on the shrub. The horses would return more strong and healthy. Sea-buckthorn
is a special food that is used to help astronauts maintain their health in space [55].
Since ancient times, Sea-buckthorn berries have been used for their beneficial effects on blood
circulation, skin regeneration, and anti-inflammatory effects. The berry contains oil, both in
the seed and in the soft parts (pulp oil from the flesh and peel). Special features of the oils are
high proportions of palmitic (16:0), oleic (18:1n-9), palmitoleic (16:1n-7), linoleic (18:2n-6), and
α-linolenic (18:3n-3) acids as well as vitamin E, carotenoids, and sterols [56].
While the seed oil is rich in linoleic and α-linolenic acids, the pulp oil is a very rich source
of palmitoleic acid.  This acid is an essential  fatty acid that is  rare to find in the natural
form. Macadamia nuts are the only other source of Omega-7 fatty acids and only in trace
amounts [57].
The pulp oil provides a 1:1 ratio of Omega-3/Omega-6. The pulp can be consumed either as a
juice or a puree. All the components of the berry contain flavonoides, but the seed residues
and the leaves are the most important sources of flavonoides (particularly quercetin, isorham‐
netin, kaempherol) [58]. Flavonoides and vitamin C have anti-inflammatory effects and act
through a synergic mechanism [59].
The Sea-buckthorn fruit is a very rich source of vitamin C (695 mg per 100 grams), about 12
times greater than oranges, placing Sea-buckthorn fruit among the most enriched plant sources
of vitamin C [60].
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The origin (subspecies of more than seven) and harvesting time of the berries, as well as oil
isolation technology, influence the oil composition [61]. The amounts of bioactive compounds
in sea buckthorn berry vary depending on the subspecies, area and year of cultivation, and the
maturity of the berries [62].
The method used for extracting Sea-buckthorn influences the potency and the quality of the
oil. Cold pressing, hot pressing, solvent extraction, and maceration in other carrier oils are the
most used ways for Sea-buckthorn oil extraction, but each method have its own disadvantages.
For example, cold-pressing may be ideal, but the extraction rate is quite low. Hot-pressing
destroys healthy nutrients and solvent extraction may contaminate the oil with hazardous
solvents. The best way to obtain Sea-buckthorn oil is through supercritical CO2-extraction.
Potentially all compounds of the berry, including flavonols, carotenoids, fatty acids, toco‐
pherols, tocotrienos, and phytosterols of the pulp oil, can affect the metabolic profile. Clinical
and experimental studies have demonstrated a wide range of positive effects of the sea
buckthorn oils and flavonoides on the lipid profile. Animal and in vitro studies have suggested
that sea buckthorn oils [63, 64, 65] and alcohol extracts and flavonoid preparations [66, 67, 68,
69] have antioxidant and anti-inflammatory activities and may beneficially affect serum
glucose and triglyceride concentrations. The effect was observed in participants who had a
metabolic profile that reflected higher cardiometabolic risk.
In  two  clinical  studies  [70,  71]  involving  healthy  men,  the  intake  for  8  weeks  of  Sea-
buckthorn juice versus placebo or supplementation with 5 g of Sea-buckthorn berry oil for
4 weeks versus coconut oil control had no significant influence on the lipid profile (total
cholesterol, LDL-c, HDL-c, and triglycerides), but decreased moderately the susceptibility
of LDL to oxidation [71].
In healthy, normolipidemic adults having healthy diets, consumption of Sea-buckthorn berry
did not affect the circulating concentration of lipid markers, but increased the fasting plasma
concentration of quercetin and isorhamnetin indicating that Sea-buckthorn berry is a good
dietary source of flavonols [72].
There is a paucity of clinical and animal experiments focused on Sea-buckthorn oil effects on
dyslipidemia associated to obesity and the studies are lacking in childhood obesity. Also, in
some published data, the tested oils are not defined and some studies should have a better
design. The influence of the oils on the plasma lipid levels needs further investigation.
In the experimental study done on white albino rabbits fed with high cholesterol, CO2 extracted
Sea-buckthorn seed oil treatment (1 ml for 30 days) had significant anti-atherogenic and
cardioprotective activity. The treatment increased the HDL-c plasma levels and restored the
acetylcholine-induced vasorelaxant effect to that of normal values [73].
A randomized, double-blind, crossover study including two 4-week periods with either 3
g/day of black currant seed oil or 2.8 g/day of fish oil separated by a 4-week washout period
was done on 15 healthy females. The results showed that black currant seed oil had minor
changes on serum n3 fatty acids. Serum levels of LDL cholesterol were lower (p < 0.05) after
black currant seed oil compared to fish oil. Plasma glucose concentration decreased during the
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fish oil supplementation (p < 0.05). The results underline the beneficial effects of berries and
berry seed oils on serum lipid profile [74].
In a study group including 49 atopic dermatitis patients who took 5 g (10 capsules) of seed
oil, pulp oil, or paraffin oil daily for 4 months, a significant (p < 0.05) increase in the level
of high-density lipoprotein cholesterol from 1.38 to 1.53 mmol/L was observed in the pulp
oil group [75].
It was demonstrated that a high-MUFA, cholesterol-lowering diet may be superior to a low-
fat diet because it lowers triglyceridemia and does not decrease the plasma level of HDL
cholesterol [76].
C16:1n7-palmitoleate is known as an adipose tissue-derived lipid hormone that works at the
crosstalk between lipid and sugar metabolism. The acid stimulates muscle insulin action and
suppresses hepatosteatosis [77]. The following lines will present the effects of palmitoleic acid
on insulinodependent tissues.
In vitro studies done on rat L6 skeletal muscle cells, it was demonstrated that palmitoleic might
facilitate uptake and utilization of glucose by upregulation of the activities of the glucose
transporters GLUT1 and GLUT4 [78].
On a spontaneous model of obese type 2 diabetes rats, researchers demonstrated that repeated
administration of palmitoleic acid increased insulin sensitivity by down-regulating mRNA
expressions of proinflammatory adipocytokine genes (TNFα and resistin) in white adipose
tissue and by decreasing hepatic lipid accumulation. Palmitoleic acid down-regulates the
mRNA of lipogenic genes (as an example, SREBP-1) in the liver and reduces both the plasma
triglyceride and hepatic triglyceride levels [79].
It is worth mentioning the effects of C16, n-7 on pancreatic tissue. It was demonstrated that
palmitoleic and oleic acids prevent the deleterious effects of saturated fatty acids and high
glucose on human pancreatic beta-cell turnover and function via Bcl-2 [80].
In a recent randomized crossover study, 80 overweight women were divided into four groups
with different supplements intake for 30 days: dried Sea-buckthorn berries, Sea-buckthorn oil,
Sea-buckthorn phenolics ethanol extract mixed with maltodextrin (1:1), or frozen bilberries.
Sea-buckthorn-induced effects were mainly on serum triglycerides and very-low-density
lipoprotein (VLDL) and its subclasses in the groups with higher metabolic risk. From the
supplements, Sea-buckthorn oil induced a decreasing trend in serum total, IDL, and LDL
cholesterol and apolipoprotein B in participants with the baseline metabolome of higher
cardiometabolic risk [81].
In the Sea-buckthorn, most antioxidants appear to accumulate in the seeds relative to the pulp,
leaves, or stem despite most flavonoids being in the leaves. The total phenolic content of the
leaves is high and is between 47.06–66.03 mg/g rutin equivalents (RE) [82].
Phenolic compounds and flavonoids ameliorate bodyweight, blood glucose, and serum lipid
profile. Also flavonoids from seeds and leaves have anti-obesity and hypoglycemic effect.
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Clinical studies have demonstrated that the berry and the ethanol fraction from Sea-buckthorn
pulp has beneficial effects on postprandial glucose and insulin levels [83].
Experimental studies done in diabetic rats demonstrated that flavonoids present in water
extracts of Sea-buckthorn seeds have hypoglycemic and triglyceride-lowering effect [84].
The fibers and polyphenols in Sea-buckthorn (Hippophaë rhamnoides) extraction residues
delay also the postprandial lipemia [85].
Quercetin, as an important flavonoid in the Sea-buckthorn, has also hypolipidemic effect [86].
Quercetin inhibits fatty acid and triacylglycerol synthesis in rat liver cells [87].
In vitro studies demonstrated that quercetin and isorhamnetin have protective effects against
oxidized LDL-induced endothelial cell injuries. The flavonoids’ beneficial effects might derive
from their antioxidant activity and from their capability in modulating the expression of eNOS
(endothelial nitric oxide synthase) and LOX-1(lipooxygenase-1) [66].
There are some molecules that are (currently known to be) unique to Sea-buckthorn named
flavonoid glycosides [88] and they have antioxidant activity.
High-fat diet obese C57BL/6J mice treated with 70% ethanolic extract of Sea-buckthorn at 500–
1,000 mg/kg bodyweight over 13 weeks had lower hepatic and serum total cholesterol, lower
hepatic triglycerides and serum leptin level versus non-treated mice. Triglyceridemia and
insulinemia were similar in the studied group. The study demonstrated that the Sea-buckthorn
intervention was effective in preventing body weight gain and fat accumulation in the liver.
The molecular mechanism of this effect is the increase of the hepatic mRNA expression of
peroxisome proliferator-activated receptor (PPAR) α and PPAR-γ while the level of the hepatic
key enzyme in the fatty acid synthase was decreased [89].
Many compounds from Sea-buckthorn help lose extra weight. Omega-7 in Sea-buckthorn
sends messages to the brain, telling it to stop storing calories as excess fat. Sea-buckthorn oil
stimulates healthy bowel moves, thereby protecting cell membranes from oxidative and
physical stress.
In overweight or obese women, the intake of different berries and berry fractions for 33 days
with washout periods of 30–39 days have resulted in positive effects such as a significantly
decrease in the waist circumference and in the level of vascular cell adhesion and intercellular
adhesion molecules [90].
2.3. Association of the atherogenic indexes with antropometric, inflammatory, oxidative
stress and endothelial dysfunctional markers in childhood obesity
It was demonstrated that in obese children with metabolic syndrome, there is a positive
association between the high waist circumference and the atherogenic index (total cholesterol/
HDL-c) [91].
Endothelial dysfunction, inflammation, and oxidative stress are present in childhood obesity.
Especially during puberty, there are some pro-inflammatory and pro-oxidative changes
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associated with a relative insulin resistance. The association of the inflammatory and oxidative
stress markers with the high value of the apo B/apo A1 ratio in obese children underlies the
action in the cluster of different pathogenic mechanisms, augmenting the atherosclerosis
development [26, 92].
Apolipoproteins B and A-1 are proposed as markers with value in pediatric lipid risk assess‐
ment. High apo B and low apo A-1 levels, usually present in obese children and adolescents
reflect a lipoprotein profile predisposing to the development of subclinical atherosclerosis in
adulthood [93], [94].
The concentrations of plasma apolipoprotein (apo) B are often increased in childhood obesity,
partly due to the hepatic overproduction of apo B containing lipoproteins [95,96].
Many researchers consider apo B as a better predictor of vascular risk than LDL because
apo B, in comparison with LDL, is more strongly associated with other cardiovascular risk
factors [97].
3. Diet and weight loss
A comparative study between severely obese children versus moderately obese children
demonstrated a markedly more unfavorable cardio-metabolic risk profile in the first group.
The study highlights that severely obese children need to receive particular attention regarding
obesity treatment [98].
A recent study demonstrated that the strongest negative predictor of weight loss is waist
circumference. The study underscores that obese children with abdominal fat distribution
need more intensive interventions [99].
In a review about the impact of dietary and physical activity in obese children, including the
studies that have been done in the last 35 years, demonstrated that diet-only and diet-plus-
exercise interventions resulted in weight loss and metabolic profile improvement. Diet-only
intervention reduced triglycerides and LDL levels, while diet-plus-exercise interventions
reduced fasting glycaemia and insulinemia and increased HDL-c concentration [100].
In obese children and adolescents, weight loss improved the values of the parameters included
in the metabolic syndrome criteria with the exception of HDL-c concentration. The reduction
in fasting triglycerides concentration (but not waist circumference) was the only significant
predictor of metabolic syndrome change [101].
Diet modifications and physical activity have been included in obesity management, but have
shown relatively limited success among severely obese children and adolescents. However,
the parents of obese children should know that a healthy lifestyle is important for better
physical and mental health no matter how much or how little weight is lost. The physician
should help patients to cope obesity for psychosocial functioning and must motivate them to
make use of the available healthcare resources.
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Pharmacotherapy for obesity has side effects (growth problems, lessened self-esteem, unheal‐
thy weight-control mechanisms) and frequently fails to be efficacious because obesity is a
multifactorial, polygenic disease [102,103].
4. Own results
We did some studies in obese children and adolescents (n = 41 and n = 48) and analytical
evaluations were performed before and immediately after supplements were administrated.
In one study we gave Sea-buckthorn pulp oil (800 mg/day for 60 days) and placebo, and in
another study we gave Omega-3 fatty acids (DHA 130 mg and EPA 25 mg) associated with
vitamins (A 200 µg, D 1.25 µg, E 2.5 mg, and C 30 mg). As a control, we enrolled 30 lean children.
All the children under medications or those with chronic disease (endocrine, inflammatory,
or hereditary diseases) or smokers were excluded. The participants were instructed not to
change their lifestyle (dietary and drinking habits, physical activity) during the whole studies
and not to take any additional medication including vitamin supplements.
The atherogenic indexes (calculated either as total cholesterol/HDL-c or apoB/apo-A1) were
calculated in obese children. Higher values for atherogenic indexes have predictive values for
atherosclerosis development. The atherogenic indexes were correlated with other cardiovas‐
cular risk factors such as: waist circumference (Figure 1), C reactive protein (CRP), GGT activity
(Figure 2), diastolic blood pressure, and malondialdehyde (MDA)-marker of lipid peroxida‐
tion (Figure 3). The multiple associations of atherogenic index with dyslipidemia, antropo‐
metric, inflammatory, and oxidative stress markers underline that in obesity there is a cluster
of patogenic mechanisms that contribute to atherosclerosis. Also, the atherogenic indexes were
associated with subclinical atherosclerotic disease markers as carotid intima media thickness-
CIMT (positive correlation) (Figure 4) and with brachial artery flow-mediated dilation-FMD
(Flow Mediated Dilatation (negative correlation) (Figure 5) [104, 105].
Figure 1. Correlation between atherogenic index and waist circumference (r = 0.33). The atherogenic index was calcu‐
lated as the ratio between total cholesterol/HDL-c.
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Figure 2. Correlation between GGT activity with aterogenic index (r = 0.42). The atherogenic index was calculated as
the ratio between total cholesterol/HDL-c.
By hydrolyzing the glutathione, the GGT has a pro-oxidant effect. Also, the products of the
GGT reaction may themselves lead to increased free radical production, particularly in the
presence of iron. High serum GGT activity was positively associated with the risk of coronary
heart disease, type 2 diabetes mellitus, and stroke. We have demonstrated a positive correlation
between GGT activity and the cholesterol/HDL-c ratio value [104] (Figure 2).
Figure 3. Correlation between MDA and apoB/apo A-1 (r = 0.39).
There is a paucity of studies on systemic oxidative stress in childhood obesity but almost all
of them have demonstrated higher levels of serum malonyldialdehyde, a marker of lipid
peroxidation. There is a direct relation between dyslipidemia and lipid peroxidation and both
contribute to a pro-inflammatory phenotype in childhood obesity [105, 106, 107] (Figure 5).
NADPH oxidase activity (respiratory burst) in monocytes is increased in childhood obesity
and together with serum lipid peroxidation contributes to an increased systemic oxidative
stress [105].
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Our research team demonstrated that in obese children versus lean ones, plasma total
cholesterol and triglycerides were higher, while HDL-c level was lower. LDL-c concentrations
were similar in the studied groups. The treatment (800 mg/day, for 60 days) with Sea-buck‐
thorn pulp oil (obtained by cold pressing) reduced significantly the total plasma cholesterol,
the apo B/apo A-I ratio and the plasma triglycerides. A weak improvement of HDL-c and LDL-
c levels was noticed [105]. We consider that the composition of the Sea-buckthorn pulp oil rich
in MUFA and phytosterols is responsible for this effect [108].
Figure 4. Correlation between apo B/apo A-1 with CIMT (r = 0.38).
Figure 5. Correlation between apo B/apo A-1 with FMD (r = -0.36).
Dyslipidemia, inflammation, insulin resistance, and oxidative stress are important culprits
for atherosclerosis in obesity.  Hyperleptinemia and hypoadiponectinemia represent links
between inflammation and vascular dysfunction in obese children. Atherosclerosis begins
with endothelium dysfunction and insulin resistance is an important trigger. Puberty alerts
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some of the inflammatory markers associated with endothelial dysfunction in obese children
and  leptin  concentration  rises.  Leptin  is  a  biomarker  of  vascular  dysfunction,  while
adiponectin improves endothelial cells function. In our study done on 48 obese children,
the intake of  Omega-3 fatty acids (DHA 130 mg and EPA 25 mg) associated with vita‐
mins  (A 200 µg,  D 1.25  µg,  E  2.5  mg,  and C 30  mg)  for  3  months  has  resulted in  im‐
proved  lipid  profile.  The  values  for  total  cholesterol,  LDL-c,  and  triglycerides  were
decreased, while the HDL-c level was increased [109]. We showed that in the obese children,
supplements with Omega-3 fatty acids improved not only the lipid profile,  but also the
blood pressure values and inflammatory markers. By lowering leptin, increasing adiponec‐
tin, and by decreasing the HOMA-IR values, Omega-3 PUFA reduces the risk of cardiovas‐
cular disease development in adulthood [109].
According to the ATP III (adult treatment panel) modified criteria [110] in our studies, more
than 55% of the obese children had triglyceridemia higher than 100 mg/dl and triglyceridemia
was correlated with ALT (Alanine aminotransferase) activity. Our results are in accordance
with others. In a study done on 700 overweight and obese children aged 7–18 years, ALT
activity was correlated with BMI, waist circumference, blood pressure values, triglyceridemia,
and insulin resistance [111]. Calcaterra et al. proposed the high value of ALT as a screening
marker for metabolic syndrome in obese children [112].
In one of our studies, we divided the obese children in two groups: hypertriglyceridemic waist
fenotype (n = 17) and obese nonhypertriglyceridemic (n = 24). Modified ATP III cut points for
serum triglycerides (≥110 mg/dL) and waist circumference (≥90th percentile for age and sex)
were used to divide obese children. Metabolic and inflammatory parameters were measured
before and after Sea-buckthorn pulp oil intake (800 mg/day, 60 days) and the best improvement
of the measured plasma variables was observed in hypertriglyceridemic waist phenotype
obese children. We demonstrated that high serum values for triglycerides were associated with
low values for HDL-C and the treatment reduced significantly the levels of triglycerides and
improved the HDL-C concentration [113].
Hepatic de novo lipogenesis is augmented in hypertriglyceridemic waist phenotype obese
children and this can be demonstrated by the high values of ALT. In our study, treatment with
Sea-buckthorn pulp oil reduced ALT activity and triglyceridemia and improved blood
pressure levels. By reducing triglyceridemia and by improving the blood pressure levels, Sea-
buckthorn pulp oil may prevent metabolic syndrome in obese children [105, 113]. The study
underlines that treatment with Sea-buckthorn pulp oil should be recommended in hypertri‐
glyceridemic waist phenotype obese children. Also, in obese children, the intake of Omega-3
fatty acids (DHA 130 mg and EPA 25 mg per day) associated with vitamins (A 200 µg, D 1.25
µg, E 2.5 mg, and C 30 mg) for 3 months reduced the blood pressure values (systolic and
diastolic) significantly [109].
Some of the most important effects for Omega-3 supplements and Sea-buckthorn pulp oil
supplements are to prevent atherosclerosis and to reverse the CIMT values [105,109].
In a high-fat diet mouse model, we induced non-alcoholic fatty liver disease to NMRI mice
and the treatment with normocaloric/normolipidic diet and Omega-3 fatty acids (DHA 130 mg
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and EPA 25 mg per day) had reversed liver histopatological results from steatohepatitis to
normal aspect and improved the plasma lipid profile [114].
5. Treatment of dyslipidemia associated to childhood obesity
Both in adults and in children, the extent of atherosclerotic lesions is significantly correlated
with a modified serum lipid profile (increased total and LDL cholesterol, triglycerides, low
HDL cholesterol) together with elevated blood pressure and waist circumference.
Reversal of vascular functional abnormalities with early therapy with statins and supplemen‐
tation with antioxidant vitamins and Omega-3 fatty acids has been observed in children with
familial hypercholesterolemia.
According to an AHA Scientific Statement, “LDL cholesterol lowering drug therapy is
recommended only in those children ≥10 years of age whose LDL cholesterol remains ex‐
tremely elevated after an adequate 6- to 12-month trial of diet therapy. Drug therapy was to
be considered for children with LDL cholesterol levels ≥190 mg/dL and in those with LDL
cholesterol ≥160 mg/dL together with either the presence of ≥2 other cardiovascular disease
risk factors or a positive family history of premature cardiovascular disease” [34].
Omega-3 PUFA represents the first choice in treating hypertrigliceridemia in childhood
obesity because they do not have adverse reactions, they are safe, and they have good tolerance.
Also, different Sea-buckthorn fractions do not have side effects [110–86] and they have great
future as food supplements in preventing obesity complications. Future research work will
show if the beneficial changes of the supplements revert back if the treatment is stopped.
Cook and Kavey recommend that “any medication except Omega-3 fish oil in youths with
combined dyslipidemia should be undertaken only with the assistance of a lipid specialist” [3].
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